uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
Provided By GlobeNewswire
Last update: Feb 3, 2025
~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~
~ Company expects to initiate enrollment of second dose cohort in the first quarter of 2025 ~
Read more at globenewswire.com
